Compare · DXCM vs OFIX
DXCM vs OFIX
Side-by-side comparison of DexCom Inc. (DXCM) and Orthofix Medical Inc. (OFIX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and OFIX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $31.19B, about 74.1x OFIX ($421.2M).
- Over the past year, DXCM is up 8.6% and OFIX is down 15.3% - DXCM leads by 23.9 points.
- DXCM has been more active in the news (8 items in the past 4 weeks vs 7 for OFIX).
- DXCM has more recent analyst coverage (25 ratings vs 10 for OFIX).
- Company
- DexCom Inc.
- Orthofix Medical Inc.
- Price
- $82.98+0.39%
- $10.61+2.22%
- Market cap
- $31.19B
- $421.2M
- 1M return
- +12.04%
- -8.02%
- 1Y return
- +8.60%
- -15.32%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 1992
- News (4w)
- 8
- 7
- Recent ratings
- 25
- 10
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Orthofix Medical Inc.
Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Extremities. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The Global Extremities segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1987 and is headquartered in Lewisville, Texas.
Latest DXCM
- Director Foletta Mark G sold $330,640 worth of shares (4,000 units at $82.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by DexCom Inc.
- DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Dexcom Reports Second Quarter 2026 Financial Results
- Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
- Executive Chair Sayer Kevin R sold $2,041,999 worth of shares (26,756 units at $76.32) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 328,970 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
Latest OFIX
- SEC Form S-8 filed by Orthofix Medical Inc.
- SEC Form 10-Q filed by Orthofix Medical Inc.
- Orthofix Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Orthofix Reports Second Quarter 2026 Results Reflecting Continued Operational Progress
- MedTech Pioneer Max Reinhardt Joins eXeX to Drive Canopus Platform Growth
- Orthofix to Participate in Upcoming Investor Conferences
- Orthofix to Report Second Quarter 2026 Financial Results
- Orthofix Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Pres, Global Ops & Qual Mcpherron Aviva sold $34,425 worth of shares (3,670 units at $9.38), decreasing direct ownership by 5% to 66,330 units (SEC Form 4) to cover withholding tax
- Director Bazaar Alan Lee was granted 14,965 shares, increasing direct ownership by 30% to 65,489 units (SEC Form 4)